Lee M. Rauch serves as Chief Executive Officer, Director of the Company. Ms. Rauch has more than 25 years of experience in the biotech and pharmaceutical industries, helping build successful companies from pre-clinical stage to advanced clinical development. During this time, she has held several executive positions with Global Blood Therapeutics (NASDAQ: GBT), Onyx Pharmaceuticals, Nuon Therapeutics, POINT Biomedical, COR Therapeutics, and Syntex Corporation (Roche Bioscience). She has also served as a consultant to the biotech and pharmaceutical industry. Prior to joining miRagen, she was the Executive in Residence at Columbia Technology Ventures. Until 2015, she held the role of Chief Business Officer at GBT, where she oversaw overall business functions. Prior to GBT, she was President and CEO of Nuon Therapeutics, an auto-immune and inflammatory disease company. Before Nuon, she was the Interim Chief Business Officer and V.P. of Corporate Development at Onyx. Earlier in her career she was a founding member of McKinsey & Co.'s Pharmaceutical Practice. Ms. Rauch received her M.B.A. in finance from the University of Chicago and a B.S. in Chemistry from Arizona State University.
Lee Rauch is 60, she's been the Chief Executive Officer und Director of Miragen Therapeutics Inc since 2020. There are 3 older and 6 younger executives at Miragen Therapeutics Inc. The oldest executive at Miragen Therapeutics Inc is Arlene Morris, 68, who is the Independent Director.
Lee's mailing address filed with the SEC is C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER, CO, 80301.
Over the last 8 years, insiders at Miragen Therapeutics Inc have traded over $636,110 worth of Miragen Therapeutics Inc stock and bought 1,041,411 units worth $5,368,137 . The most active insiders traders include Bennett S Lebow, Bruce Booth und Paul D Rubin. On average, Miragen Therapeutics Inc executives and independent directors trade stock every 91 days with the average trade being worth of $2,345,685. The most recent stock trade was executed by Global Master Fund Lp Logos on 9 November 2020, trading 476,667 units of MGEN stock currently worth $2,268,935.
Miragen Therapeutics Inc executives and other stock owners filed with the SEC include: